Misc - 宇原　久

Orange pigmentation spots on the sole may be from a stink bug

Hisashi Uhara, Tasuku Sano, Tomomi Miyake, Ryuhei Okuyama

Journal of Dermatology ( Blackwell Publishing Ltd )  43 ( 10 ) 1247 - 1248  2016年10月

速報，短報，研究ノート等（学術雑誌）  

DOI PubMed

皮膚 メラノーマ・他 KEYNOTE-041 進行性悪性黒色腫の日本人患者を対象としたMK-3475の第Ib相試験

横田 憲二, 竹之内 辰也, 藤本 学, 尹 浩信, 内 博史, 猪爪 隆史, 清原 祥夫, 宇原 久, 中川 和彦, 古川 洋志, 和田 秀文, 野口 一夫, 嶋本 隆司, 山崎 直也

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  54回   WS30 - 1  2016年10月

5-Hydroxymethylcytosine as a putative marker for erosive adenomatosis of the nipple

Yuko Takazawa, Tomohiro Edamitsu, Kazuma Maeno, Eisaku Ogawa, Hisashi Uhara, Shigeo Kawachi, Ken-Ichi Ito, Ryuhei Okuyama

Journal of Dermatology ( Blackwell Publishing Ltd )  43 ( 5 ) 579 - 580  2016年05月

速報，短報，研究ノート等（学術雑誌）  

DOI PubMed

Inhibition of epidermal growth factor receptor induces tumor necrosis factor-α via activation of peroxisome proliferator-activated receptor-γ and nuclear factor-κB in sebocytes: A possible pathogenesis of papulopustular rash

Atsuko Ashida, Eisaku Ogawa, Hisashi Uhara, Tomonobu Koizumi, Ryuhei Okuyama

Journal of Dermatological Science ( Elsevier Ireland Ltd )  82 ( 1 ) 53 - 56  2016年04月

速報，短報，研究ノート等（学術雑誌）  

DOI PubMed

5-Hydroxymethylcytosine is a useful marker to differentiate between dermatofibrosarcoma protuberans and dermatofibroma

Y. Mikoshiba, E. Ogawa, R. Uchiyama, A. Uchiyama, H. Uhara, R. Okuyama

Journal of the European Academy of Dermatology and Venereology ( Blackwell Publishing Ltd )  30 ( 1 ) 130 - 131  2016年01月

速報，短報，研究ノート等（学術雑誌）  

DOI PubMed

A Place for BRAFV600E Mutation-specific Immunohistochemistry Alongside Cell-free DNA Mutation Detection in Melanoma Reply

Atsuko Ashida, Hisashi Uhara, Asuka Mikoshiba, Kaori Sakaizawa, Naomi Kumagai, Hiroshi Koga, Ryuhei Okuyama

ACTA DERMATO-VENEREOLOGICA ( ACTA DERMATO-VENEREOLOGICA )  96 ( 3 ) 427 - 427  2016年

速報，短報，研究ノート等（学術雑誌）  

Violaceous and Petechial Persistent Plantar Plaques: A Quiz

Atsuko Ashida, Hisashi Uhara, Asuka Mikoshiba, Kaori Sakaizawa, Naomi Kumagai, Hiroshi Koga, Ryuhei Okuyama

ACTA DERMATO-VENEREOLOGICA ( ACTA DERMATO-VENEREOLOGICA )  96 ( 3 ) 427 - +  2016年

その他  

DOI

Histopathological improvement of scleroderma induced by paclitaxel in a patient with breast cancer

Atsuko Ohashi, Akane Minagawa, Atsuko Ashida, Hiroshi Koga, Hisashi Uhara, Ryuhei Okuyama

JOURNAL OF DERMATOLOGY ( WILEY-BLACKWELL )  42 ( 12 ) 1198 - 1199  2015年12月

速報，短報，研究ノート等（学術雑誌）  

DOI

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma

N. Yamazaki, Y. Kiyohara, H. Uhara, S. Fukushima, H. Uchi, N. Shibagaki, A. Tsutsumida, S. Yoshikawa, R. Okuyama, Y. Ito, T. Tokudome

Cancer Chemotherapy and Pharmacology   76 ( 5 ) 997 - 1004  2015年11月  [査読有り]   [ 国際誌 ]

　概要を見る

© 2015 The Author(s). Purpose: Ipilimumab is designed to block cytotoxic T-lymphocyte antigen-4 to augment antitumor T cell responses. In studies of predominantly Caucasian patients with advanced melanoma, ipilimumab was associated with durable response, long-term survival benefit, and a manageable safety profile. This phase II study assessed the safety of ipilimumab in Japanese patients with unresectable stage III or IV melanoma. Methods: Patients received ipilimumab 3 mg/kg every 3 weeks for four doses. The database lock for the original analysis was in August 2014. Overall survival, progression-free survival, and data on deaths were based on an updated, follow-up analysis (database lock April 2015). Results: Data are reported from 20 patients. Fifteen patients (75 %) received all four doses of ipilimumab during induction. Twelve patients (60 %) had at least one drug-related adverse event (AE), and no patients discontinued due to a drug-related AE. There were no deaths related to study drug. The most common drug-related AEs were rash (n = 7), pyrexia (n = 3), increased aspartate aminotransferase (AST; n = 3), and increased alanine aminotransferase (ALT; n = 3). Twelve patients (60 %) reported immune-related AEs (irAEs); most frequent were skin (n = 9) and liver (n = 3) disorders. Grade 3 irAEs were ALT and AST elevation (n = 2) and diabetes mellitus (n = 1). Two patients had a partial response and two had stable disease, yielding a 20 % disease control rate. Median overall survival and progression-free survival were 8.71 and 2.74 months, respectively. Conclusion: Ipilimumab 3 mg/kg had a manageable AE profile in this Japanese patient population with clinical outcomes similar to that in Caucasian patients. ClinicalTrials.gov identifier: NCT01990859.

DOI PubMed

Brown nodule on the lower eyelid: A quiz

Shiho Shirota, Akane Minagawa, Hiroshi Koga, Masanobu Momose, Hisashi Uhara, Ryuhei Okuyama

Acta Dermato-Venereologica ( Medical Journals/Acta D-V )  95 ( 8 ) 1037  2015年11月

速報，短報，研究ノート等（学術雑誌）  

DOI PubMed

Primary cutaneous nocardiosis caused by Nocardia concava

Kenta Nakamura, Fuminao Kamijo, Tatsuya Negishi, Takehisa Matsumoto, Ryuhei Okuyama, Hisashi Uhara

Journal of Dermatology ( Blackwell Publishing Ltd )  42 ( 11 ) 1121 - 1122  2015年11月

速報，短報，研究ノート等（学術雑誌）  

DOI PubMed

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma

N. Yamazaki, H. Uhara, S. Fukushima, H. Uchi, N. Shibagaki, Y. Kiyohara, A. Tsutsumida, K. Namikawa, R. Okuyama, Y. Otsuka, T. Tokudome

Cancer Chemotherapy and Pharmacology   76 ( 5 ) 969 - 975  2015年11月  [査読有り]   [ 国際誌 ]

　概要を見る

© 2015 The Author(s). Purpose: Ipilimumab (IPI), a monoclonal antibody against immune-checkpoint receptor cytotoxic T lymphocyte antigen-4, is designed to enhance antitumor T cell function. IPI 10 mg/kg plus dacarbazine (DTIC) significantly improved overall survival in a phase 3 study involving predominantly Caucasian patients, with an adverse event (AE) profile similar to that of IPI monotherapy. We conducted a single-arm, phase 2 study to evaluate the safety and efficacy of IPI plus DTIC in Japanese patients. Methods: Previously untreated patients with unresectable stage III or IV melanoma received IPI 10 mg/kg plus DTIC 850 mg/m2 every 3 weeks for four doses (q3w × 4), followed by DTIC q3w × 4 and then IPI every 12 weeks until disease progression or intolerable toxicity. Results: All 15 treated patients reported drug-related AEs, the most common of which were increases in alanine aminotransferase (n = 12, 80 %) and aspartate aminotransferase (n = 11, 73 %). Treatment-related serious AEs were reported in 11 (73 %) patients. Nine patients (60 %) discontinued treatment due to drug-related toxicities. Immune-related AEs (irAEs) were reported in 14 patients (93 %). The most frequent irAEs were liver (n = 12, 80 %) and skin (n = 10, 67 %) toxicities. Five deaths were reported; all were caused by progressive disease. Efficacy evaluation showed one complete response, one partial response and four patients with stable disease. Best overall response rate was 13 % (2/15), and the disease control rate was 40 % (6/15). The study was terminated early due to frequent, high-grade liver toxicities. Conclusions: IPI 10 mg/kg plus DTIC 850 mg/m2 was not considered tolerable in the Japanese patient population. ClinicalTrials.gov identifier: NCT01681212.

DOI PubMed

The role of sentinel lymph node biopsy in the management of invasive extramammary Paget's disease: multi-center, retrospective study of 151 patients (vol 79, pg 38, 2015)

Yasuhiro Fujisawa, Koji Yoshino, Yoshio Kiyohara, Takafumi Kadono, Yozo Murata, Hisashi Uhara, Naohito Hatta, Hiroshi Uchi, Shigeto Matsushita, Tatsuya Takenouchi, Toshihiko Hayashi, Manabu Fujimoto, Kuniaki Ohara

JOURNAL OF DERMATOLOGICAL SCIENCE ( ELSEVIER IRELAND LTD )  80 ( 1 ) 79 - 79  2015年10月

その他  

DOI

Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in Japanese patients with advanced melanoma: Preliminary report

N. Yamazaki, Y. Kiyohara, H. Uhara

EUROPEAN JOURNAL OF CANCER ( ELSEVIER SCI LTD )  51   S110 - S110  2015年09月

研究発表ペーパー・要旨（国際会議）  

皮膚がん分子標的治療の現状と新薬開発状況 (特集 固形がんの分子標的薬 : 基礎研究から創薬・開発・臨床まで) -- (疾患・臓器からみた固形がん分子標的治療)

宇原 久

日本臨床 ( 日本臨床社 )  73 ( 8 ) 1391 - 1397  2015年08月

CiNii

進行期悪性黒色腫におけるipilimumabの2つの国内第2相試験における安全性マネージメント

宇原 久, 山崎 直也, 清原 祥夫, 内 博史, 福島 聡, 柴垣 直孝, 堤田 新, 奥山 隆平, 吉川 周佐, 並川 健二郎, 徳留 拓人

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集 ( 日本皮膚悪性腫瘍学会 )  31回   149 - 149  2015年07月

進行期悪性黒色腫患者におけるipilimumab単独療法第2相臨床試験

福島 聡, 清原 祥夫, 宇原 久, 内 博史, 柴垣 直孝, 堤田 新, 吉川 周佐, 奥山 隆平, 伊藤 嘉紀, 山崎 直也

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集 ( 日本皮膚悪性腫瘍学会 )  31回   149 - 149  2015年07月

化学療法未治療進行期悪性黒色腫患者におけるipilimumabのDTIC併用国内第2相臨床試験

内 博史, 宇原 久, 福島 聡, 柴垣 直孝, 清原 祥夫, 堤田 新, 奥山 隆平, 並川 健二郎, 大塚 康司, 山崎 直也

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集 ( 日本皮膚悪性腫瘍学会 )  31回   149 - 149  2015年07月

日本人の悪性黒色腫のBRAF、NRAS、KIT変異率と臨床所見

境澤 香里, 芦田 敦子, 伊東 孝通, 藤澤 康弘, 緒方 大, 松下 茂人, 藤井 一恭, 福島 聡, 柴山 慶継, 八田 尚人, 竹之内 辰也, 上原 治朗, 奥山 隆平, 山崎 直也, 宇原 久

日本皮膚科学会雑誌 ( (公社)日本皮膚科学会 )  125 ( 4 ) 940 - 940  2015年04月

これからのがん免疫療法と今後の展望

清原 祥夫, 山崎 直也, 宇原 久, 福島 聡, 山口 研成, 室 圭, 山本 信之, 里内 美弥子, 瀬戸 貴司, 井上 彰, 後藤 功一, 鵜殿 平一郎, 西川 博嘉, 山中 竹春

Immuno-Oncology Frontier ( (株)メディカルレビュー社 )  1 ( 1 ) 14 - 21  2015年01月